MiMedx Group (MDXG) Stock Forecast, Price & News

MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions

Is MiMedx Group a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MiMedx Group stock.
View analyst ratings for MiMedx Group or view top-rated stocks.

When is MiMedx Group's next earnings date?

MiMedx Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for MiMedx Group.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) released its quarterly earnings data on Tuesday, May, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. During the same quarter in the previous year, the business posted ($0.09) EPS.
View MiMedx Group's earnings history.

What guidance has MiMedx Group issued on next quarter's earnings?

MiMedx Group updated its FY 2022 earnings guidance on Monday, March, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $266.40 million-$273.60 million, compared to the consensus revenue estimate of $267.30 million.

What price target have analysts set for MDXG?

2 Wall Street analysts have issued 12-month price objectives for MiMedx Group's stock. Their forecasts range from $8.50 to $23.00. On average, they expect MiMedx Group's stock price to reach $15.75 in the next year. This suggests a possible upside of 336.3% from the stock's current price.
View analysts' price targets for MiMedx Group or view top-rated stocks among Wall Street analysts.

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the following people:

• Mr. Peter Martin Carlson CPA, Chief Financial Officer (Age 58, Pay $787.81k)
• Mr. William F. Hulse IV, Gen. Counsel & Chief Admin. Officer (Age 48, Pay $733.69k)
• Dr. Rohit Kashyap Ph.D., Pres of Wound Care & Surgical (Age 51, Pay $741.29k)
• Dr. Robert Benjamin Stein M.D., Ph.D., Pres of Regenerative Medicine & Biologics Innovation (Age 71, Pay $731.25k)
• Mr. Timothy R. Wright MBA, CEO & Director (Age 64)
• Mr. Scott M. Turner, Sr. VP of Operations & Procurement (Age 57)
• Mr. William L. Phelan, Sr. VP & Chief Accounting Officer
• Mr. John J. Howarth, Sr. VP of Investor Relations
• Mr. Mark P. Graves, Sr. VP & Chief Compliance Officer (Age 56)
• Hilary Dixon, VP of Investor Relations & Corp. Strategic Communications

Who are some of MiMedx Group's key competitors?

Some companies that are related to MiMedx Group include Nevro (NVRO), Embecta (EMBC), Paragon 28 (FNA), Atrion (ATRI), Silk Road Medical (SILK), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), Intersect ENT (XENT), Cerus (CERS), OrthoPediatrics (KIDS), Longview Acquisition Corp. II (LGV), Alphatec (ATEC), Treace Medical Concepts (TMCI), AngioDynamics (ANGO) and Artivion (AORT).
View all of MDXG's competitors.

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.42%), Vanguard Group Inc. (4.01%), State Street Corp (3.89%), Richmond Brothers Inc. (2.25%), Federated Hermes Inc. (1.52%) and Northern Trust Corp (0.87%). Company insiders that own MiMedx Group stock include Mark Graves, Peter M Carlson, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends for MiMedx Group.

Which institutional investors are selling MiMedx Group stock?

MDXG stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Citigroup Inc., Royal Bank of Canada, Northern Trust Corp, Raymond James & Associates, Richmond Brothers Inc., State Board of Administration of Florida Retirement System, and Group One Trading L.P.. Company insiders that have sold MiMedx Group company stock in the last year include Mark Graves, Peter M Carlson, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse, and William Lawrence Phelan.
View insider buying and selling activity for MiMedx Group or view top insider-selling stocks.

Which institutional investors are buying MiMedx Group stock?

MDXG stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., State Street Corp, Renaissance Technologies LLC, Fisher Asset Management LLC, ClariVest Asset Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., and Isthmus Partners LLC.
View insider buying and selling activity for MiMedx Group or or view top insider-buying stocks.

How do I buy shares of MiMedx Group?

Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $3.61.

How much money does MiMedx Group make?

MiMedx Group has a market capitalization of $409.19 million and generates $258.61 million in revenue each year. The company earns $-10.28 million in net income (profit) each year or ($0.170010) on an earnings per share basis.

How many employees does MiMedx Group have?

MiMedx Group employs 811 workers across the globe.

What is MiMedx Group's official website?

The official website for MiMedx Group is www.mimedx.com.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The company can be reached via phone at (770) 651-9100, via email at [email protected], or via fax at 678-384-6741.